These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31220420)

  • 1. γδ cell-based immunotherapy for cancer.
    Lo Presti E; Corsale AM; Dieli F; Meraviglia S
    Expert Opin Biol Ther; 2019 Sep; 19(9):887-895. PubMed ID: 31220420
    [No Abstract]   [Full Text] [Related]  

  • 2. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
    Li Y; Li G; Zhang J; Wu X; Chen X
    Front Immunol; 2020; 11():619954. PubMed ID: 33664732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
    Park JA; Santich BH; Xu H; Lum LG; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends.
    Barros MS; de Araújo ND; Magalhães-Gama F; Pereira Ribeiro TL; Alves Hanna FS; Tarragô AM; Malheiro A; Costa AG
    Front Immunol; 2021; 12():729085. PubMed ID: 34630403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
    Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
    J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A close look at current γδ T-cell immunotherapy.
    Ma L; Feng Y; Zhou Z
    Front Immunol; 2023; 14():1140623. PubMed ID: 37063836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. γδ T Cells in Tumor Microenvironment.
    Imbert C; Olive D
    Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells.
    Guo Q; Zhao P; Zhang Z; Zhang J; Zhang Z; Hua Y; Han B; Li N; Zhao X; Hou L
    Cancer Immunol Immunother; 2020 Dec; 69(12):2571-2587. PubMed ID: 32588076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Advances in γδ T Cell-Based Tumor Immunotherapy.
    Lo Presti E; Pizzolato G; Gulotta E; Cocorullo G; Gulotta G; Dieli F; Meraviglia S
    Front Immunol; 2017; 8():1401. PubMed ID: 29163482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy.
    Van Acker HH; Campillo-Davo D; Roex G; Versteven M; Smits EL; Van Tendeloo VF
    Cytokine Growth Factor Rev; 2018 Jun; 41():54-64. PubMed ID: 29773448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer.
    Mikulak J; Oriolo F; Bruni E; Roberto A; Colombo FS; Villa A; Bosticardo M; Bortolomai I; Lo Presti E; Meraviglia S; Dieli F; Vetrano S; Danese S; Della Bella S; Carvello MM; Sacchi M; Cugini G; Colombo G; Klinger M; Spaggiari P; Roncalli M; Prinz I; Ravens S; di Lorenzo B; Marcenaro E; Silva-Santos B; Spinelli A; Mavilio D
    JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31689241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. γδ T Cells: Unexpected Regulators of Cancer Development and Progression.
    Fleming C; Morrissey S; Cai Y; Yan J
    Trends Cancer; 2017 Aug; 3(8):561-570. PubMed ID: 28780933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. γδ cells and tumor microenvironment: A helpful or a dangerous liason?
    Lo Presti E; Di Mitri R; Pizzolato G; Mocciaro F; Dieli F; Meraviglia S
    J Leukoc Biol; 2018 Mar; 103(3):485-492. PubMed ID: 29345336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. γδ T cells bring unconventional cancer-targeting to the clinic - again.
    Garber K
    Nat Biotechnol; 2020 Apr; 38(4):389-391. PubMed ID: 32265560
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion and Adoptive Transfer of Human Vδ2
    Sharma A; Zumwalde NA; Gumperz JE
    Methods Mol Biol; 2019; 1884():57-72. PubMed ID: 30465195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with γδ T-cells: the future is there.
    Kabelitz D; Yin Z
    Immunotherapy; 2024; 16(11):705-708. PubMed ID: 38940301
    [No Abstract]   [Full Text] [Related]  

  • 20. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.